{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:59:46Z","timestamp":1781161186139,"version":"3.54.1"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jfma.2026.01.023","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:20:03Z","timestamp":1769030403000},"page":"S65-S72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S1","title":["Updates on hereditary transthyretin amyloidosis polyneuropathy"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-0914","authenticated-orcid":false,"given":"Te-Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5204-154X","authenticated-orcid":false,"given":"Sung-Ju","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4707-1861","authenticated-orcid":false,"given":"Hsueh-Wen","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3188-8482","authenticated-orcid":false,"given":"Sung-Tsang","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6499-5789","authenticated-orcid":false,"given":"Chi-Chao","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jfma.2026.01.023_bib1","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.jfma.2026.01.023_bib2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"10.1016\/j.jfma.2026.01.023_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1474-4422(23)00334-4","article-title":"Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment","volume":"22","author":"Adams","year":"2023","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2026.01.023_bib4","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy","volume":"29","author":"Adams","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/75.3.408","article-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.jfma.2026.01.023_bib6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/jnnp-2023-332180","article-title":"Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers","volume":"95","author":"Beauvais","year":"2024","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.28026","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: recommendations from a panel of experts","volume":"69","author":"Karam","year":"2024","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.jfma.2026.01.023_bib8","first-page":"511","article-title":"Expert consensus of the Taiwan society of cardiology on the diagnosis and treatment of cardiac amyloidosis","volume":"39","author":"Wang","year":"2023","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.jfma.2026.01.023_bib9","first-page":"13","article-title":"Unique phenotypes with corresponding pathology in late-onset hereditary transthyretin amyloidosis of A97S vs. V30M","author":"Hsueh","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"10.1016\/j.jfma.2026.01.023_bib10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/acn3.778","article-title":"Clinical and genetic profiles of hereditary transthyretin amyloidosis in Taiwan","volume":"6","author":"Chao","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jfma.2026.01.023_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.jfma.2026.01.023_bib14","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jfma.2026.01.023_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/ane.13035","article-title":"Hereditary transthyretin-related amyloidosis","volume":"139","author":"Finsterer","year":"2019","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"10.1016\/j.jfma.2026.01.023_bib16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajmg.1320600606","article-title":"Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in povoa do varzim and vila do conde (north of Portugal)","volume":"60","author":"Sousa","year":"1995","journal-title":"Am J Med Genet"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/13506129.2013.860027","article-title":"Frequency of the transthyretin Val30Met mutation in the northern Swedish population","volume":"21","author":"Olsson","year":"2014","journal-title":"Amyloid"},{"issue":"1\u20132","key":"10.1016\/j.jfma.2026.01.023_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2008.02.019","article-title":"Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus","volume":"270","author":"Kato-Motozaki","year":"2008","journal-title":"J Neurol Sci"},{"issue":"s2","key":"10.1016\/j.jfma.2026.01.023_bib19","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.3233\/JND-150091","article-title":"Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in sicily, an Italian endemic area","volume":"2","author":"Mazzeo","year":"2015","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"10.1016\/j.jfma.2026.01.023_bib20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.25433","article-title":"Skin nerve pathology: biomarkers of premanifest and manifest amyloid neuropathy","volume":"85","author":"Chao","year":"2019","journal-title":"Ann Neurol"},{"issue":"sup1","key":"10.1016\/j.jfma.2026.01.023_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/13506129.2019.1582479","article-title":"Ala97Ser mutation is common among ethnic Chinese Malaysians with transthyretin familial amyloid polyneuropathy","volume":"26","author":"Low","year":"2019","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.jfma.2026.01.023_bib22","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/ana.27203","article-title":"A multicenter study of hereditary transthyretin amyloidosis in China","volume":"97","author":"Chu","year":"2025","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jfma.2026.01.023_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2022.105313","article-title":"Transthyretin: its function and amyloid formation","volume":"155","author":"Ueda","year":"2022","journal-title":"Neurochem Int"},{"issue":"8","key":"10.1016\/j.jfma.2026.01.023_bib24","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s41588-020-0669-3","article-title":"Guidelines for human gene nomenclature","volume":"52","author":"Bruford","year":"2020","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.jfma.2026.01.023_bib25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/10408363.2024.2350379","article-title":"Transthyretin mutagenesis: impact on amyloidogenesis and disease","volume":"61","author":"Almeida","year":"2024","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2026.01.023_bib26","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/01.LAB.0000059937.11023.1F","article-title":"Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology","volume":"83","author":"Sekijima","year":"2003","journal-title":"Laboratory investigation; a journal of technical methods and pathology"},{"issue":"2","key":"10.1016\/j.jfma.2026.01.023_bib28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/13506129.2020.1841623","article-title":"New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden","volume":"28","author":"Gorram","year":"2021","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2026.01.023_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/13506129.2012.665400","article-title":"Genotype--phenotype correlation in FAP","volume":"19","author":"Zeldenrust","year":"2012","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506120802193720","article-title":"Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population","volume":"15","author":"Hellman","year":"2008","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.jfma.2026.01.023_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/hmg\/ddi051","article-title":"Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease","volume":"14","author":"Soares","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jfma.2026.01.023_bib32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/B978-0-444-52902-2.00038-2","article-title":"Transthyretin familial amyloid polyneuropathy","volume":"115","author":"Plante-Bordeneuve","year":"2013","journal-title":"Handb Clin Neurol"},{"issue":"11","key":"10.1016\/j.jfma.2026.01.023_bib33","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","article-title":"Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: Early- vs late-onset form","volume":"59","author":"Koike","year":"2002","journal-title":"Arch Neurol"},{"issue":"Pt 10","key":"10.1016\/j.jfma.2026.01.023_bib34","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/brain\/122.10.1951","article-title":"Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features","volume":"122","author":"Misu","year":"1999","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.jfma.2026.01.023_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","article-title":"Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas","volume":"83","author":"Koike","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.jfma.2026.01.023_bib36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmg.31.5.351","article-title":"Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate","volume":"31","author":"Holmgren","year":"1994","journal-title":"J Med Genet"},{"issue":"11","key":"10.1016\/j.jfma.2026.01.023_bib37","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/(SICI)1097-4598(199811)21:11<1478::AID-MUS17>3.0.CO;2-X","article-title":"Transthyretin Tyr77 familial amyloid polyneuropathy: a clinicopathological study of a large kindred","volume":"21","author":"Blanco-Jerez","year":"1998","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib38","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/ene.14698","article-title":"Early changes of nerve integrity in preclinical carriers of hereditary transthyretin Ala117Ser amyloidosis with polyneuropathy","volume":"28","author":"Chiang","year":"2021","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.jfma.2026.01.023_bib39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1212\/WNL.0b013e3181ec7fda","article-title":"Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser","volume":"75","author":"Yang","year":"2010","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jfma.2026.01.023_bib40","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/acn3.51635","article-title":"Cardiomyopathy correlates to nerve damage in p.A117S late-onset transthyretin amyloid polyneuropathy","volume":"9","author":"Lin","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib41","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ana.26965","article-title":"Amyloid neuropathy: from pathophysiology to treatment in light-chain amyloidosis and hereditary transthyretin amyloidosis","volume":"96","author":"Chompoopong","year":"2024","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib42","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1038\/s41467-021-27481-4","article-title":"Structural basis for transthyretin amyloid formation in vitreous body of the eye","volume":"12","author":"Iakovleva","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jfma.2026.01.023_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4610","article-title":"A molecular basis for tetramer destabilization and aggregation of transthyretin Ala97Ser","volume":"32","author":"Wang","year":"2023","journal-title":"Protein Sci"},{"issue":"5","key":"10.1016\/j.jfma.2026.01.023_bib44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/jnen\/nlac022","article-title":"Distinct patterns of amyloid pathology in autopsies of transthyretin S77Y and A97S amyloidosis: significance of symptomatology and cell biology","volume":"81","author":"Chang","year":"2022","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"10.1016\/j.jfma.2026.01.023_bib45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1440-1827.1997.tb04508.x","article-title":"Late onset type I familial amyloidotic polyneuropathy: presentation of three autopsy cases in comparison with 19 autopsy cases of the ordinary type","volume":"47","author":"Takahashi","year":"1997","journal-title":"Pathol Int"},{"issue":"6","key":"10.1016\/j.jfma.2026.01.023_bib46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0046-8177(91)90227-G","article-title":"Familial amyloidotic polyneuropathy type 1 in Kumamoto, Japan: a clinicopathologic, histochemical, immunohistochemical, and ultrastructural study","volume":"22","author":"Takahashi","year":"1991","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.jfma.2026.01.023_bib47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/joim.12585","article-title":"One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition","volume":"281","author":"Suhr","year":"2017","journal-title":"J Intern Med"},{"issue":"21","key":"10.1016\/j.jfma.2026.01.023_bib48","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1212\/WNL.0000000000003362","article-title":"Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy","volume":"87","author":"Koike","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib49","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/acn3.51930","article-title":"Nerve pathology of microangiopathy and thromboinflammation in hereditary transthyretin amyloidosis","volume":"11","author":"Yeh","year":"2024","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"7","key":"10.1016\/j.jfma.2026.01.023_bib50","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1093\/brain\/awaf028","article-title":"Transthyretin variants impact blood\u2013nerve barrier and neuroinflammation in amyloidotic neuropathy","volume":"148","author":"Chao","year":"2025","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ana.24972","article-title":"Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy","volume":"82","author":"Ebenezer","year":"2017","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/jns.12680","article-title":"Minimal invasive biopsies are highly sensitive for amyloid detection in hereditary transthyretin amyloidosis with polyneuropathy","volume":"30","author":"Leonardi","year":"2025","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/13506129.2018.1564903","article-title":"Electrophysiological demyelinating features in hereditary ATTR amyloidosis","volume":"26","author":"Ohashi","year":"2019","journal-title":"Amyloid"},{"issue":"7","key":"10.1016\/j.jfma.2026.01.023_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70277","article-title":"Intracutaneous amyloid deposition is associated with nerve conduction studies deterioration in presumed asymptomatic pathogenic variant TTR carriers","volume":"32","author":"Schulz","year":"2025","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.jfma.2026.01.023_bib56","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.clinph.2020.01.022","article-title":"Quantitative sudomotor test helps differentiate transthyretin familial amyloid polyneuropathy from chronic inflammatory demyelinating polyneuropathy","volume":"131","author":"Fortanier","year":"2020","journal-title":"Clin Neurophysiol"},{"issue":"2","key":"10.1016\/j.jfma.2026.01.023_bib57","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ana.24438","article-title":"Sudomotor innervation in transthyretin amyloid neuropathy: pathology and functional correlates","volume":"78","author":"Chao","year":"2015","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.jfma.2026.01.023_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2016-315262","article-title":"Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy","volume":"88","author":"Cortese","year":"2017","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"12","key":"10.1016\/j.jfma.2026.01.023_bib59","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/acn3.51924","article-title":"Amyloid detection and typing yield of skin biopsy in systemic amyloidosis and polyneuropathy","volume":"10","author":"Pinton","year":"2023","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"9","key":"10.1016\/j.jfma.2026.01.023_bib60","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/acn3.51636","article-title":"Cutaneous amyloid is a biomarker in early ATTRv neuropathy and progresses across disease stages","volume":"9","author":"Freeman","year":"2022","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"2","key":"10.1016\/j.jfma.2026.01.023_bib61","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/path.2411","article-title":"Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis","volume":"216","author":"Ihse","year":"2008","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00415-020-10127-8","article-title":"Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers","volume":"268","author":"Salvalaggio","year":"2021","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.jfma.2026.01.023_bib63","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/joim.20019","article-title":"Neck triangle nerve enlargement in hereditary transthyretin amyloidosis correlates with changes in the autonomic, cardiac, and gastrointestinal systems","volume":"296","author":"Hsueh","year":"2024","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib64","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/mus.24168","article-title":"Ultrasound evaluation in transthyretin-related amyloid neuropathy","volume":"50","author":"Granata","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jfma.2026.01.023_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120329","article-title":"Magnetic resonance imaging of dorsal root ganglion in a pre-symptomatic subject with familial amyloid polyneuropathy transthyretin E61K","volume":"440","author":"Murakami","year":"2022","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.jfma.2026.01.023_bib66","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/CIRCIMAGING.112.000367","article-title":"Reduced myocardial 123-Iodine metaiodobenzylguanidine uptake","volume":"6","author":"Coutinho","year":"2013","journal-title":"Circ, Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.jfma.2026.01.023_bib67","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1212\/WNL.0000000000005777","article-title":"Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy","volume":"91","author":"Lozeron","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib68","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jns.12403","article-title":"Peripheral neuropathy symptoms in wild type transthyretin amyloidosis","volume":"25","author":"Wajnsztajn","year":"2020","journal-title":"J Peripher Nerv Syst"},{"issue":"11","key":"10.1016\/j.jfma.2026.01.023_bib69","article-title":"ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American college of cardiology solution set oversight committee","volume":"81","author":"Michelle","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib70","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges","volume":"21","author":"Carvalho","year":"2015","journal-title":"Liver Transplant"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib71","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/13506129.2015.1123149","article-title":"Long-term outcome of patients with hereditary transthyretin V30M amyloidosis with polyneuropathy after liver transplantation","volume":"23","author":"Okumura","year":"2016","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1526924819853832","article-title":"Evaluating prognostic factors for liver transplantation among United States patients with hereditary transthyretin-mediated (hATTR) amyloidosis using national registry data","volume":"29","author":"Brandman","year":"2019","journal-title":"Prog Transplant"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2024.103083","article-title":"Preliminary efficacy and safety analysis of tafamidis in post-liver transplant patients with hereditary transthyretin cardiac amyloidosis","volume":"56","author":"Okumura","year":"2025","journal-title":"Arch Med Res"},{"issue":"24","key":"10.1016\/j.jfma.2026.01.023_bib74","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jfma.2026.01.023_bib75","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/acn3.52158","article-title":"Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis","volume":"11","author":"Chao","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"10.1016\/j.jfma.2026.01.023_bib76","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib77","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/ene.13510","article-title":"Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy","volume":"25","author":"Gundapaneni","year":"2018","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib78","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2017.1301419","article-title":"Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial","volume":"24","author":"Keohane","year":"2017","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.jfma.2026.01.023_bib80","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jfma.2026.01.023_bib81","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib82","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13506129.2024.2420809","article-title":"PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study","volume":"32","author":"Suhr","year":"2025","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib83","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/GIM.0b013e31815f524f","article-title":"A systematic review of perceived risks, psychological and behavioral impacts of genetic testing","volume":"10","author":"Heshka","year":"2008","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/cjn.2021.34","article-title":"Canadian guidelines for hereditary transthyretin amyloidosis polyneuropathy management","volume":"49","author":"Alcantara","year":"2022","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib85","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1055\/s-0043-1764412","article-title":"Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition","volume":"81","author":"Pinto","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.023_bib86","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/hearts6010006","article-title":"A general overview of transthyretin cardiac amyloidosis and summary of expert opinions on pre-symptomatic testing and management of asymptomatic patients with a focus on transthyretin V122I","volume":"6","author":"Sawalha","year":"2025","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib87","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41431-020-00758-w","article-title":"Opportunistic genomic screening. Recommendations of the european society of human genetics","volume":"29","author":"De Wert","year":"2021","journal-title":"Eur J Hum Genet"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2026.01.023_bib88","article-title":"Guidelines for genetic counselling in ATTR amyloidosis","volume":"10","author":"Sequeiros","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1016\/j.jfma.2026.01.023_bib89","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/gim.2013.73","article-title":"ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing","volume":"15","author":"Green","year":"2013","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.023_bib90","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jgc4.1676","article-title":"Expanded carrier screening for reproductive risk assessment: an evidence-based practice guideline from the national society of genetic counselors","volume":"32","author":"Sagaser","year":"2023","journal-title":"J Genet Counsel"},{"issue":"9","key":"10.1016\/j.jfma.2026.01.023_bib91","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis","volume":"84","author":"Kitaoka","year":"2020","journal-title":"Circ J"},{"issue":"6","key":"10.1016\/j.jfma.2026.01.023_bib92","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1007\/s12325-022-02139-9","article-title":"Clinical and genetic evaluation of people with or at risk of hereditary ATTR amyloidosis: an expert opinion and consensus on best practice in Ireland and the UK","volume":"39","author":"Gillmore","year":"2022","journal-title":"Adv Ther"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626000410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626000410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:36:49Z","timestamp":1781159809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664626000410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":92,"alternative-id":["S0929664626000410"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2026.01.023","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on hereditary transthyretin amyloidosis polyneuropathy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2026.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}